Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose. The Food and Drug Administration issued a warning in May 2015 notifying that patients using this class of anti-diabetic drugs may develop DKA. Risk factors for DKA development among patients who take SGLT-2 inhibitors include carbohydrate intake/starvation or acute illness. In the current report, we aimed to present a case of euglycemic DKA using dapagliflozin treatment.
Dapagliflozin sodium-glucose co-transporter 2 inhibitors euglycemic ketoacidosis
Birincil Dil | İngilizce |
---|---|
Konular | İç Hastalıkları |
Bölüm | Case Reports |
Yazarlar | |
Yayımlanma Tarihi | 7 Mart 2021 |
Gönderilme Tarihi | 8 Şubat 2021 |
Kabul Tarihi | 6 Mart 2021 |
Yayımlandığı Sayı | Yıl 2021 Cilt: 3 Sayı: Supplement 1 |